Author: Seth Conners

  • Dixons Carphone Shares Slump

    Shares of Dixons Carphone (DC.L), a European mobile phone and electrical goods retailer, plummeted after the company cut its dividend in fiscal 2019 and forecast a “significant” loss for the UK Mobile business in the financial year currently underway. Sales fell by 1% to 10.43 billion pounds ($13.14 billion) during the 12 months that ended April 27, from 10.53 billion […]

  • Consumer Sentiment Gauge Ticks Lower in June

    A key gauge of consumer sentiment ticked lower in June, missing analysts’ estimates as survey participants lowered their growth prospects for the national economy in the wake of tariffs on Chinese exports and a softening in employment growth. The University of Michigan’s preliminary consumer sentiment index, which is widely viewed as an indicator of the future course of the national […]

  • Asian ADRs Slip Lower in Trading

    American depositary receipts of Asian stocks were trading 2.51% lower at 1,427.65 on the BNY Mellon Asia 50 ADR Index on Tuesday. In North Asia, the gainers were led by electricity provider Korea Electric Power (KEP) and educational services provider Puxin (NEW), which rose 4.3% and 3.9% respectively. They were followed by financial services firm Nomura (NMR) and social media […]

  • Strong Gains for Consumer Discretionary Stocks

    Top Consumer Stocks WMT -0.02% MCD +0.51% DIS +0.79% CVS +3.6% KO -0.36% Consumer stocks were posting sizable gains in recent trade, with shares of consumer staples companies in the S&P 500 climbing 0.6% this afternoon while shares of consumer discretionary firms in the S&P 500 were ahead 2%. Among consumer stocks moving on news: (+) Yunji (YJ) was 2% […]

  • Iovance Biotherapeutics Says Cervical Cancer Drug Has 11% Response Rate in Study

    Iovance Biotherapeutics (IOVA) said Friday its drug LN-145 achieved an 11% complete response rate in a follow-up study of patients with advanced cervical cancer. The company noted that the median duration of response (DOR) had yet to be reached in the trial. “The duration of response of current second line treatments for advanced cervical cancer are in the range of […]